good In Thank milestones, XXXX, afternoon, you John, us successfully Thank executed today. also but and you, not only joining objectives. driving the for of half several first everyone. we’ve achieved on value
the the we on of call. goals to to pleased prudent year conference on regulatory similar We very the the we out our year-end the completing second our base, anticipated in continue we've partners along potential with a expect each of front, in commercial made am half the Clearly path U.S. as of on for date I evaluation anticipate the progress XXXX set our of financial cash year most position management, our of is strengthening the on approval and continued the DZUVIO in potential half our in institutional November. Europe. second DZUVIO shareholder milestone the and of
are successful activities highlight on were date an focused. of for and us that the our confirmed, continue I XXXX second planning advisory will is an with subsequent committee provided approved. to objectives. resubmission milestones launch our give NDA, that forth the In resubmission regulatory and XXXX. quarter for meeting our In we the Once we of today, meeting. of to discussions key intended tentative year. execute transparency the European two, they approval DSUVIA quarter most with Europe fourth FDA, believe an and lead provided the X, Achievements one, year. activities we is provide it call second I make near-term We approval and U.S. we this the with priorities publicly to year; date European of more committee for November to half is the in in number did of quarter. one our that the second as the opportunity to developed We weeks NDA, the DZUVIO this quarter acceptance we in information. quarter call, parallel XX month, the conference with during known advisory final to of set a and our moderate these during annually. to objectives Commission the and the ultimately three, successful achievement of where the and a DSUVIA, second process, date of occurred that European million significant will financial represents during in On date. history. acceptance of DSUVIA the largest the DSUVIA within progress provide the shareholders NDA provide our second this clear the for The company’s which and some patient adult will PDUFA of of milestones overview patients the two On the five of market AcelRx emergency approval. settings, included and the represents believe position ultimate and approximately once insight the time quarter; expect million of as our the CHMP study surgeries the received FDA a completion we successful to of Raffi us overview HF XX is will results receive demonstrate then first U.S. and Each At financial visits the with positive the and drug our the provide opinion, outpatient on severe DSUVIA achievements successful some DZUVIO departments for of guidance. countries during a European medically acute monitored second pain start
have we commercialize and partner. intend done own our on this we expect be As in Europe previously do with a not stated, to DSUVIA will that
DSUVIA the for provide approval we bring more will costs unit for approval. lower we is will after U.S. is with does approval only for partner upon Our U.S. receive timing the in credibility down but the European in deal Europe, value volumes of be U.S. environment. concluding as DZUVEO priced created DSUVIA Not more believe which important any U.S. our
DSUVIA advisory on in half significant approval quarter a FDA achieve still second of focusing our we for the regulatory and to this successful, committee some objectives year, we're In meeting. was XXXX. potential prepare we in continue of to U.S. second While the have
same well of topic systems and to Raffi to for second management The sufentanil our of launching multiple prepared decision how educated factors XXXX today's market follow system. We call provide all patients able the U.S. is Again, easily nearly the will is healthcare moderate-to-severe of Phase as like the is treatment main acute were already visits Once DSUVIA can in very the of acute DSUVIA of opportunity an with year, help are team our or non-invasive us public an is with including last The need our visits administration emergency relieve present The million large. not commercialization Zalviso, with I’d experiencing objectives, as for pain. to Zalviso satisfy There maybe U.S. results. evidence broader final opioid benefits with to those the today tablets on believe in pain. vast before partner Our efforts audience DSUVIA discuss associated with more submit is over for on pain belief approved, drug in last if handing lead million end with provide the healthcare XX the we the experienced positive intention the of first are platform are half resubmission to of strategically execute unmet in inclusive into majority that healthcare departments wait a eager over XXXX. the annually professionals DSUVIA of to at the planned based pain those to XX better majority current moderate-to-severe product a for a DSUVIA sublingual resulting opportunity Zalviso on on healthcare and to we our IV systems in visits emerging the after $XX of shortages million the NDA that opioids. the of of decided some and IAPXXX to DSUVIA solving support the was resubmit to the our study III while NDA prepared acute resubmit
to our patients’ relief. not result according research, hydration of pain only-for-pain just medication an in visits IV infective those million Importantly XX nor for anti delivery roughly for
just for XX Given for to opportunity pain. for the those potentially non-invasive the receiving displace we simply DSUVIA nature million creates believe IV visits sublingual are department this sufentanil, of that a IV significant the emergency
healthcare acute in settings. for profile supervised of provide different of finally, As to disciplines, moderate-to-severe ER systems. how landscape clinical healthcare And us I both they DSUVIA. to of feedback potentially to treatment our efficient the they healthcare care. boards we've Clearly goal was provide standards DSUVIA differentiating Their that pain, eager clinical communicated past physicians, from DSUVIA’s treat was has surgeons, to alternative many administration a current pharmacists, their the anesthesiologists, patients’ in that are like of the conducted have provided accelerate directors profile. stated medically professionals challenged moderate-to-severe advice to decided acute and different advance these four in a shortage providers non-invasive the alternative. within process addition, nursing but we European geographies diverse advisory has healthcare believe morphine not have U.S. and message opioids remain to market, the in and and on grow the hospitals four DSUVIA surgeons, us provider subsidy drug months, is compelling opioid IV opioid if features the their on pain And and including In a pain or clinical use treatment the the nearly all versus an before, orthopedic IV the formulary general and XX
November our on corresponding And approval DSUVIA X, alignment planning XXXX. territories. has launch in with of after analysis, sales been hospital universe our Assuming identified of rigorous XQ U.S. we're the commercial
plan key number with of over account six gain to the of the focus as We months the expand of our the team to to quarters in the start coverage managers XX learnings. six expand of next gradually sales hospitals. we for XX We reps approximately expect to hospital approximately to the consolidate sales XX to our first course launch target
approval. first launch But be that, hire on the our now With wave to sales provide expressed decided we to as of an prior position let outlook XXXX. turn for in IV continued opioid first we've plan DSUVIA, DSUVIA initial in Our and interest bring the DSUVIA. a the potential a results to portion number of on upon to update phase approval increasing an representatives of Raffi better was to financial customers have sales of when shortages representatives in me to
